Equities
Health CareMedical Equipment and Services
  • Price (EUR)29.18
  • Today's Change0.48 / 1.67%
  • Shares traded14.98k
  • 1 Year change+0.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform2
Hold7
Sell0
Strong Sell0

Share price forecast in EUR

The 11 analysts offering 12 month price targets for SCHOTT Pharma AG & Co KgaA have a median target of 33.00, with a high estimate of 39.00 and a low estimate of 31.00. The median estimate represents a 13.09% increase from the last price of 29.18.
High33.7%39.00
Med13.1%33.00
Low6.2%31.00

Dividends

Historical dividend information is not available for SCHOTT Pharma AG & Co KgaA.
Div growth (TTM)--
More ▼

Earnings history & estimates in EUR

On Aug 29, 2024, SCHOTT Pharma AG & Co KgaA reported 3rd quarter 2024 earnings of 0.31 per share.
The next earnings announcement is expected on Dec 12, 2024.
Average growth rate+22.35%
SCHOTT Pharma AG & Co KgaA reported annual 2023 earnings of 1.01 per share on Jan 26, 2024.
More ▼

Revenue history & estimates in EUR

SCHOTT Pharma AG & Co KgaA had 3rd quarter 2024 revenues of 253.59m. This bettered the 223.77m consensus of the 3 analysts covering the company. This was 10.97% above the prior year's 3rd quarter results.
Average growth rate+3.59%
SCHOTT Pharma AG & Co KgaA had revenues for the full year 2023 of 898.60m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.